Issue 3, 2017

A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics

Abstract

Cell wall biosynthesis inhibitors (CBIs) have historically been one of the most effective classes of antibiotics. They are the most extensively used class of antibiotics and their importance is exemplified by the β-lactams and glycopeptide antibiotics. However, this class of antibiotics has not received impunity from resistance development. In the wake of this predicament, this review presents the progress of CBIs, especially glycopeptide derivatives as antibiotics to confront antibacterial resistance. The various strategies used for the development of CBIs, their clinical status and possible directions in which this field can evolve have also been discussed.

Graphical abstract: A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics

Article information

Article type
Review Article
Submitted
21 Oct 2016
Accepted
18 Jan 2017
First published
26 Jan 2017

Med. Chem. Commun., 2017,8, 516-533

A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics

P. Sarkar, V. Yarlagadda, C. Ghosh and J. Haldar, Med. Chem. Commun., 2017, 8, 516 DOI: 10.1039/C6MD00585C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements